EUVIMEDOpdag EUVIMED
BeobachtungsstudieOpen access · CC BY 4.0

Delayed urticaria during treatment with anti‐ CGRP monoclonal antibodies in migraine

Christoph T Berger iD, Federico Burguet Villena, Severin B Vogt, Lukas Heydrich, Karin Hartmann, Athina Papadopoulou

Headache: The Journal of Head and Face Pain · 2026-05 · 66 (5) · 1193-1199

DOI: 10.1111/head.70082 ↗

At a glance

Beobachtungsstudie in Headache: The Journal of Head and Face Pain, published online on 2026-03-15. Written by Christoph T Berger and 5 co-authors. Institution: University Center for Immunology, University Hospital Basel, Basel, Switzerland. Major MEDLINE topics: Antibodies, Monoclonal, Calcitonin Gene-Related Peptide, Migraine Disorders, Urticaria. Cited 1 times so far (Crossref); 19 references. The full text is freely available (open access, CC BY 4.0). Funded by: Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Objective

To characterize clinical presentation and management of urticaria associated with calcitonin gene‐related peptide (CGRP) ‐targeting monoclonal antibodies (mAbs) for migraine prophylaxis.

Background

CGRP‐targeting mAbs are effective in migraine prophylaxis, but have been associated with hypersensitivity reactions, including urticaria. The underlying mechanisms, risk factors, and therapeutic consequences of these anti‐CGRP mAb‐related hypersensitivity reactions remain poorly understood.

Methods

We performed a retrospective case series with descriptive analysis on five patients who developed urticaria after anti‐CGRP mAb administration. Timing of reactions, history of urticaria, re‐exposure strategies including premedication, and clinical outcomes were analyzed by chart review.

Results

Urticaria occurred after the first injection in three patients and after the third or sixth injection in two. Onset was delayed (12–48 h) in all patients, indicating a non‐IgE‐mediated hypersensitivity. Four of five patients had a prior history of urticaria. All patients were re‐exposed: two to the same anti‐CGRP mAb and three to a different. Three patients received H1‐antihistamine premedication. All premedicated patients in this series tolerated re‐exposure, irrespective of switching. One patient experienced worsening urticaria with repeated dosing without premedication despite negative allergy testing, but later tolerated the same anti‐CGRP mAb with premedication. In contrast, urticaria or angioedema recurred in two patients who switched anti‐CGRP mAb without premedication. One subsequently tolerated rimegepant.

Conclusion

Anti‐CGRP mAb‐associated urticaria in this case series was delayed and likely non‐immunoglobulin E (non‐IgE)‐mediated. Our experience supports that in selected patients with delayed urticaria, individualized management, including H1 antihistamine premedication, may allow continuation of effective migraine prophylaxis. Larger cohorts are needed to identify risk factors and to inform general management recommendations.

Subjects

MeSH terms (MEDLINE)

Antibodies, MonoclonalCalcitonin Gene-Related PeptideMigraine DisordersUrticariaAdultFemaleHumansMaleMiddle AgedRetrospective Studies

Author keywords

CGRPRimegepantallergyatopyerenumabfremanezumabgalcanezumabmigraineriskurticaria

Substances

Antibodies, MonoclonalCalcitonin Gene-Related Peptide

Authors and institutions

  • University Center for Immunology, University Hospital Basel, Basel, Switzerland.
  • Translational Immunology, Department of Biomedicine, University of Basel, Basel, Switzerland.
  • Department of Clinical Research, University Hospital Basel and University of Basel, Basel, Switzerland.
  • Clinic of Neurology, University Hospital Basel, Basel, Switzerland.
  • Clinical Pharmacology and Toxicology, University Hospital Basel, Basel, Switzerland.
  • Neurology am Kunstmuseum, Basel, Switzerland.

ORCID profiles: Christoph T Berger

Funding

  • Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung

Cite

APA

Berger, C. T., Villena, F. B., Vogt, S. B., Heydrich, L., Hartmann, K., & Papadopoulou, A. (2026). Delayed urticaria during treatment with anti‐ CGRP monoclonal antibodies in migraine. Headache: The Journal of Head and Face Pain, 66(5), 1193-1199. https://doi.org/10.1111/head.70082

Vancouver

Berger CT, Villena FB, Vogt SB, Heydrich L, Hartmann K, Papadopoulou A. Delayed urticaria during treatment with anti‐ CGRP monoclonal antibodies in migraine. Headache: The Journal of Head and Face Pain. 2026;66(5):1193-1199. doi:10.1111/head.70082

BibTeX
@article{Berger2026,
  author = {Berger, Christoph T and Villena, Federico Burguet and Vogt, Severin B and Heydrich, Lukas and Hartmann, Karin and Papadopoulou, Athina},
  title = {Delayed urticaria during treatment with anti‐ CGRP monoclonal antibodies in migraine},
  journal = {Headache: The Journal of Head and Face Pain},
  year = {2026},
  volume = {66},
  number = {5},
  pages = {1193--1199},
  doi = {10.1111/head.70082}
}
Start for free →